This finding runs in parallel with our previous study [31]; therefore, downregulation of S100β in the current treated CZ-induced model signifies the importance of S100β as a diagnostic biomarker and as an emerging therapeutic target in MS. The gene discussed is S100B; the disease is myeloid sarcoma.